Friday's Underperforming Sectors: General Contractors & Builders, Healthcare Providers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Should l Buy AGL?
Source: NASDAQ.COM
Market Performance: Hospital and medical practitioners' shares are lagging the market, down approximately 0.2% overall.
Key Contributors: Ardent Health and Agilon Health are leading the decline, with shares down 2.8% and 1.8%, respectively.
Sector Laggards: The report also mentions general contractors and builders as part of the sector laggards on the same day.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.637
Low
0.88
Averages
0.88
High
0.88
Current: 0.637
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilon Health Shares Drop 7.6% Amid Rising Cost Concerns
- Cost Increase Forecast: Agilon Health projected a 7.5% rise in costs for 2026 during the Barclays Global Healthcare Conference, raising investor concerns about future profitability, which contributed to a 7.6% drop in share price.
- Cash Flow Goals: While the company aims for free cash flow break-even by 2027 and anticipates a $125 million benefit from contracting improvements, the immediate impact of rising costs has negatively affected investor sentiment.
- Market Volatility: Agilon Health's shares have experienced 82 moves greater than 5% over the past year, indicating that today's price movement is significant to the market but does not fundamentally alter perceptions of the business.
- Year-to-Date Performance: The stock has declined 11.8% since the beginning of the year, currently trading at $0.59 per share, which is 89.5% below its 52-week high of $5.68 from April 2025, reflecting a lack of investor confidence.
See More
Halper Sadeh LLC Investigates Agilon Health Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to ensure shareholders can enforce their rights within a limited timeframe.
- Corporate Governance Reform: The investigation focuses on whether certain officers and directors of Agilon Health, Inc. (NYSE:AGL) breached their fiduciary duties, allowing long-term shareholders to seek governance reforms and potential fund recovery.
- Enhancing Transparency: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, creating a more transparent, accountable, and effectively managed organization, ultimately enhancing shareholder value.
- Legal Support and Success Stories: Halper Sadeh LLC represents investors globally against securities fraud and corporate misconduct, with attorneys instrumental in implementing corporate reforms and recovering millions for defrauded investors.
See More
Kuehn Law Investigates Agilon Health Executives' Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Agilon Health, Inc. breached their fiduciary duties to shareholders, with allegations of intentional misrepresentation in a federal securities lawsuit.
- Misleading Financial Guidance: The lawsuit claims that Agilon Health's guidance for 2025 was recklessly issued, as executives knew or should have known that the targets were unattainable, negatively impacting the company's future financial performance.
- Exaggerated Risk Management: It is also alleged that the immediate positive financial impact from strategic actions taken by Agilon to mitigate risks was materially overstated, leading to significant false or misleading statements about the company's business and operations during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased AGL stock prior to February 26, 2025, to contact their attorney immediately to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
Kuehn Law Investigates Agilon Health Executives for Breach of Duties
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether Agilon Health, Inc.'s executives breached their fiduciary duties to shareholders, as the federal securities lawsuit alleges that insiders misrepresented the company's financial outlook, impacting investor decisions.
- 2025 Financial Guidance Issues: The lawsuit claims that Agilon Health issued guidance for 2025 recklessly, knowing that the targets were unattainable, which could expose shareholders to potential financial losses due to misleading information.
- Exaggerated Strategic Impact: The investigation also highlights that the immediate financial benefits from strategic actions taken by Agilon to mitigate risks were materially overstated, leading to false and misleading statements about the company's operations and prospects.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorney promptly to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
Faruqi & Faruqi Investigates Potential Claims Against Agilon Health
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Agilon Health, reminding investors to seek lead plaintiff status by March 2, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that Agilon and its executives violated federal securities laws by issuing misleading guidance for 2025, resulting in investor losses when the truth emerged.
- Stock Price Plunge: Following Agilon's August 4, 2025 press release announcing the suspension of its 2025 financial guidance, the stock plummeted 51.5% the next day, reflecting market disappointment in the company's outlook.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Agilon's conduct to contact the firm, highlighting potential liabilities the company may face in the ongoing litigation and the rights of investors to seek recovery.
See More
Agilon Health Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Agilon Health for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and August 4, 2025, with a deadline to contact the firm by March 2, 2026.
- False Statements Allegation: The complaint alleges that Agilon made false and misleading statements regarding its 2026 guidance, which was beyond its capabilities, and overstated the effectiveness of its strategic actions to mitigate risks, resulting in investor losses when the truth emerged.
- Legal Representation Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, urging affected investors to join the lawsuit to seek compensation for their losses, highlighting its commitment to protecting investor rights globally.
See More
Agilon Health Shares Drop 7.6% Amid Rising Cost Concerns
- Cost Increase Forecast: Agilon Health projected a 7.5% rise in costs for 2026 during the Barclays Global Healthcare Conference, raising investor concerns about future profitability, which contributed to a 7.6% drop in share price.
- Cash Flow Goals: While the company aims for free cash flow break-even by 2027 and anticipates a $125 million benefit from contracting improvements, the immediate impact of rising costs has negatively affected investor sentiment.
- Market Volatility: Agilon Health's shares have experienced 82 moves greater than 5% over the past year, indicating that today's price movement is significant to the market but does not fundamentally alter perceptions of the business.
- Year-to-Date Performance: The stock has declined 11.8% since the beginning of the year, currently trading at $0.59 per share, which is 89.5% below its 52-week high of $5.68 from April 2025, reflecting a lack of investor confidence.
See More
Halper Sadeh LLC Investigates Agilon Health Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to ensure shareholders can enforce their rights within a limited timeframe.
- Corporate Governance Reform: The investigation focuses on whether certain officers and directors of Agilon Health, Inc. (NYSE:AGL) breached their fiduciary duties, allowing long-term shareholders to seek governance reforms and potential fund recovery.
- Enhancing Transparency: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, creating a more transparent, accountable, and effectively managed organization, ultimately enhancing shareholder value.
- Legal Support and Success Stories: Halper Sadeh LLC represents investors globally against securities fraud and corporate misconduct, with attorneys instrumental in implementing corporate reforms and recovering millions for defrauded investors.
See More
Kuehn Law Investigates Agilon Health Executives' Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Agilon Health, Inc. breached their fiduciary duties to shareholders, with allegations of intentional misrepresentation in a federal securities lawsuit.
- Misleading Financial Guidance: The lawsuit claims that Agilon Health's guidance for 2025 was recklessly issued, as executives knew or should have known that the targets were unattainable, negatively impacting the company's future financial performance.
- Exaggerated Risk Management: It is also alleged that the immediate positive financial impact from strategic actions taken by Agilon to mitigate risks was materially overstated, leading to significant false or misleading statements about the company's business and operations during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased AGL stock prior to February 26, 2025, to contact their attorney immediately to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
Kuehn Law Investigates Agilon Health Executives for Breach of Duties
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether Agilon Health, Inc.'s executives breached their fiduciary duties to shareholders, as the federal securities lawsuit alleges that insiders misrepresented the company's financial outlook, impacting investor decisions.
- 2025 Financial Guidance Issues: The lawsuit claims that Agilon Health issued guidance for 2025 recklessly, knowing that the targets were unattainable, which could expose shareholders to potential financial losses due to misleading information.
- Exaggerated Strategic Impact: The investigation also highlights that the immediate financial benefits from strategic actions taken by Agilon to mitigate risks were materially overstated, leading to false and misleading statements about the company's operations and prospects.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorney promptly to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
Faruqi & Faruqi Investigates Potential Claims Against Agilon Health
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Agilon Health, reminding investors to seek lead plaintiff status by March 2, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that Agilon and its executives violated federal securities laws by issuing misleading guidance for 2025, resulting in investor losses when the truth emerged.
- Stock Price Plunge: Following Agilon's August 4, 2025 press release announcing the suspension of its 2025 financial guidance, the stock plummeted 51.5% the next day, reflecting market disappointment in the company's outlook.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Agilon's conduct to contact the firm, highlighting potential liabilities the company may face in the ongoing litigation and the rights of investors to seek recovery.
See More
Agilon Health Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Agilon Health for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and August 4, 2025, with a deadline to contact the firm by March 2, 2026.
- False Statements Allegation: The complaint alleges that Agilon made false and misleading statements regarding its 2026 guidance, which was beyond its capabilities, and overstated the effectiveness of its strategic actions to mitigate risks, resulting in investor losses when the truth emerged.
- Legal Representation Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, urging affected investors to join the lawsuit to seek compensation for their losses, highlighting its commitment to protecting investor rights globally.
See More
